This Site Is Intended for US Healthcare Professionals Only
INDICATION VOQUEZNA® Triple Pak® is indicated for the treatment of Helicobacter pylori infection in adults READ MORE

Strong eradication rates with first-
line treatment1,2

NONINFERIORITY ENDPOINT IN PATIENTS WITHOUT AMOXICILLIN- OR CLARITHROMYCIN-RESISTANT STRAINS OF H. PYLORI (mITT)
Image of bar graph showing noninferiority endpoint in patients without amoxicillin- or clarithromycin-restrain strains of H. pylori. 85% eradication rate with VOQUEZNA Triple Pak. And 79% for VOQUEZNA Dual Pak and Lansoprazole Triple Therapy

Powerful H. pylori
eradication rates

Eradication rates in the per-protocol population (PP) were consistent
with the mITT population2

NONINFERIORITY ENDPOINT IN PATIENTS WITHOUT AMOXICILLIN-
OR CLARITHROMYCIN-RESISTANT STRAINS OF H. PYLORI (PP)
Image of a bar graph showing the superiority endpoint of all patients cohort. VOQUEZNA Triple Pak has an eradication rate of 81%, the VOQUEZNA Dual Pak has 77%, and Lansoprazole triple therapy has 69%."

Eradication rate for
VOQUEZNA Triple Pak
in the PP population
was 90%

Hear from Dr. Colin Howden on efficacy and safety

Dive into the VOQUEZNA data from pHalcon-HP, the largest phase 3 study conducted in H. pylori infection

Explore more data with VOQUEZNA-based regimens
SEE SAFETY PROFILERESULTS IN
ALL-PATIENTS COHORT